Volume 130, Issue 11

Cover Figure: Surface reticulocyte protein requirements restrict human infection with zoonotic Plasmodium species. See the article by Kosaisavee et al.

WASHINGTON, September 14, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma
Connors et al report very encouraging findings in a 5-year follow-up of a phase 2 study of brentuximab with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or doxorubicin, vinblastine, and dacarbazine (AVD) for upfront treatment of advanced Hodgkin lymphoma, suggesting that brentuximab may replace bleomycin as the standard of care for the treatment of high-risk patients.

Tissue-type plasminogen activator regulates macrophage activation and innate immunity
Mantuano et al describe a novel role for tissue-type plasminogen activator (tPA) in suppressing macrophage innate immune responses to lipopolysaccharide through a pathway that is independent of its fibrinolytic activity, positioning enzymatically inactive tPA as an exciting new potential therapy for inflammation and autoimmunity.

Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult
Morris and colleagues report the results of the first adult patient undergoing gene therapy for Wiskott-Aldrich syndrome (WAS), demonstrating robust and sustained engraftment of polyclonal WAS-expressing cells associated with excellent immune recovery and clinical response.

FDG-PET–driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study
Casasnovas and colleagues present the final results of a randomized phase 2 trial comparing 2 chemotherapy regimens, rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone (R-ACVBP) vs rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP14). They also suggest that quantitative FDG-PET assessment may better stratify patients to identify those needing more intensive consolidation. 

Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)
Over 50% of patients with Erdheim-Chester disease (ECD) have a BRAFV600E-activating mutation that activates the RAS-RAF-MEK-extracellular signal-regulated kinase signaling pathway, and most patients with wildtype BRAF also have MEK activation. In a Letter to Blood, Cohen Aubart and colleagues report excellent response using targeted therapy with BRAF and/or MEK inhibitors in a large cohort of ECD patients.

Flexibility and innovation in the FDA's novel regulatory approval strategies for hematologic drugs
In a Blood Forum piece illustrated with examples from recently approved drugs in hematology, Farrell et al outline the pathways available to speed approval of drugs: fast-track designation, breakthrough therapy designation, accelerated approval, and priority review.

MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts
Wallace and O’Connell offer a comprehensive review of the role of microRNAs in the pathogenesis of leukemia and project future translational applications of small regulatory RNAs in acute myeloid leukemia treatment.

How I monitor long-term and late effects after blood or marrow transplantation
Both autologous and allogeneic transplant recipients incur a lifelong risk of secondary medical problems, but there are no established screening or treatment guidelines for these sequelae. Using 4 illustrative cases, Bhatia and colleagues describe their approach to the diagnosis and management of major late posttransplant complications.


This week's complete table of contents

Why Submit to Blood?



Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.